GlassScriptPhysician profile
Paul L Dimarco
NPI 1417972605
$2,746.06
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $889 · 2021: $738.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $674.21 | 2019-2021 | |
| Janssen Biotech, INC. | $594.73 | 2019-2021 | |
| Antares Pharma, INC. | $271.28 | 2019-2021 | |
| Pfizer INC. | $164.13 | 2019-2020 | |
| Coloplast Corp | $151.37 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $138.80 | 2019-2021 | |
| Clarus Therapeutics INC. | $78.18 | 2021 | |
| Endo Pharmaceuticals INC. | $58.53 | 2019 | |
| Merck Sharp & Dohme LLC | $58.25 | 2020-2021 | |
| Therapeuticsmd, INC. | $52.35 | 2019-2020 | |
| Zyla Life Sciences, INC. | $49.28 | 2020 | |
| Myovant Sciences INC. | $38.47 | 2021 | |
| Dendreon Pharmaceuticals LLC | $33.51 | 2019-2020 | |
| Biotissue Holdings INC. | $32.94 | 2021 | |
| Foundation Medicine, INC. | $30.05 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.75 | 2021 | |
| Myriad Genetic Laboratories, INC. | $28.18 | 2020-2021 | |
| Procept Biorobotics Corporation | $27.56 | 2019 | |
| Amgen INC. | $26.63 | 2019 | |
| Blue Earth Diagnostics | $24.13 | 2019 | |
| Abbvie INC. | $23.39 | 2019-2020 | |
| Travere Therapeutics, INC. | $20.53 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.11 | 2019 | |
| 180 Medical, INC. | $19.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.41 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.14 | 2019 | |
| Amniox Medical, INC. | $17.43 | 2020 | |
| Medtronic USA, INC. | $15.33 | 2019 | |
| Metuchen Pharmaceuticals | $12.33 | 2019 | |
| Cook Medical LLC | $11.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dimarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.